 Cecilia Low Wang
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 8 | 2024 | 294 | 2.710 |
Why?
| | Diabetes Mellitus, Type 2 | 15 | 2024 | 2098 | 2.190 |
Why?
| | Blood Glucose | 13 | 2024 | 1824 | 1.530 |
Why?
| | Diabetes Mellitus | 7 | 2021 | 906 | 1.430 |
Why?
| | Hypoglycemic Agents | 6 | 2024 | 1008 | 1.140 |
Why?
| | Lower Extremity | 3 | 2021 | 337 | 1.130 |
Why?
| | Cardiovascular System | 2 | 2019 | 124 | 1.110 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 1724 | 1.060 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 399 | 0.970 |
Why?
| | Peripheral Arterial Disease | 3 | 2021 | 379 | 0.950 |
Why?
| | Prediabetic State | 2 | 2024 | 225 | 0.930 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 373 | 0.740 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 500 | 0.720 |
Why?
| | Epidemics | 1 | 2021 | 70 | 0.700 |
Why?
| | Hypoglycemia | 1 | 2024 | 386 | 0.670 |
Why?
| | Insulin Resistance | 7 | 2024 | 1078 | 0.660 |
Why?
| | Drug Approval | 1 | 2019 | 78 | 0.630 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 14 | 0.620 |
Why?
| | Glucocorticoids | 3 | 2022 | 552 | 0.610 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 222 | 0.610 |
Why?
| | Sample Size | 1 | 2018 | 115 | 0.600 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 941 | 0.590 |
Why?
| | Insulin | 10 | 2024 | 2082 | 0.580 |
Why?
| | Atherosclerosis | 3 | 2017 | 341 | 0.560 |
Why?
| | Ischemia | 1 | 2018 | 363 | 0.510 |
Why?
| | Aspirin | 1 | 2018 | 326 | 0.510 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 33 | 0.510 |
Why?
| | Drugs, Investigational | 1 | 2015 | 30 | 0.500 |
Why?
| | Hospitals | 2 | 2017 | 585 | 0.500 |
Why?
| | Patient Care Planning | 1 | 2016 | 142 | 0.490 |
Why?
| | Patient Selection | 1 | 2018 | 654 | 0.470 |
Why?
| | Endovascular Procedures | 1 | 2018 | 269 | 0.460 |
Why?
| | Algorithms | 2 | 2023 | 1490 | 0.450 |
Why?
| | Swine, Miniature | 1 | 2013 | 71 | 0.430 |
Why?
| | Insulin, Long-Acting | 2 | 2024 | 52 | 0.430 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 301 | 0.420 |
Why?
| | Obesity | 6 | 2023 | 2517 | 0.360 |
Why?
| | Hospitalization | 2 | 2016 | 1765 | 0.360 |
Why?
| | Glucose | 3 | 2024 | 904 | 0.350 |
Why?
| | Enteral Nutrition | 3 | 2024 | 157 | 0.350 |
Why?
| | Humans | 34 | 2024 | 115589 | 0.350 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 324 | 0.340 |
Why?
| | Insulin, Isophane | 2 | 2024 | 17 | 0.340 |
Why?
| | Diabetes Complications | 2 | 2013 | 212 | 0.280 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 420 | 0.260 |
Why?
| | Dietary Fats | 3 | 2012 | 289 | 0.230 |
Why?
| | Heart Failure | 1 | 2016 | 1963 | 0.220 |
Why?
| | Treatment Outcome | 5 | 2019 | 9159 | 0.220 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2006 | 239 | 0.210 |
Why?
| | Diet | 3 | 2015 | 1072 | 0.210 |
Why?
| | Glucose Intolerance | 1 | 2024 | 137 | 0.210 |
Why?
| | Endocrinology | 1 | 2023 | 69 | 0.200 |
Why?
| | Risk Factors | 5 | 2019 | 8697 | 0.200 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 71 | 0.200 |
Why?
| | Steroids | 1 | 2022 | 147 | 0.200 |
Why?
| | Dyslipidemias | 1 | 2023 | 154 | 0.190 |
Why?
| | Patient Admission | 1 | 2012 | 175 | 0.180 |
Why?
| | Dexamethasone | 1 | 2022 | 316 | 0.180 |
Why?
| | Anticholesteremic Agents | 2 | 2017 | 129 | 0.180 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 47 | 0.170 |
Why?
| | Male | 15 | 2021 | 55949 | 0.170 |
Why?
| | Diet, Reducing | 2 | 1998 | 79 | 0.170 |
Why?
| | Female | 16 | 2021 | 59913 | 0.170 |
Why?
| | Diabetic Angiopathies | 1 | 2011 | 244 | 0.160 |
Why?
| | Dietary Carbohydrates | 4 | 2012 | 135 | 0.160 |
Why?
| | Inpatients | 1 | 2012 | 380 | 0.160 |
Why?
| | Critical Illness | 1 | 2024 | 645 | 0.160 |
Why?
| | United States | 5 | 2023 | 12295 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 241 | 0.150 |
Why?
| | Middle Aged | 10 | 2018 | 26998 | 0.140 |
Why?
| | Electronic Health Records | 1 | 2023 | 805 | 0.140 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 92 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 1870 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2021 | 576 | 0.140 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 56 | 0.140 |
Why?
| | Early Growth Response Protein 1 | 1 | 2006 | 28 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 1996 | 33 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 74 | 0.130 |
Why?
| | Nausea | 1 | 2015 | 103 | 0.120 |
Why?
| | Biomarkers | 3 | 2023 | 3467 | 0.120 |
Why?
| | Hypertension | 1 | 2023 | 1064 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 776 | 0.120 |
Why?
| | Caloric Restriction | 2 | 2012 | 90 | 0.120 |
Why?
| | Mexican Americans | 1 | 2015 | 101 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2385 | 0.120 |
Why?
| | Aged | 5 | 2021 | 19250 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 40 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 275 | 0.120 |
Why?
| | Adiponectin | 1 | 2015 | 214 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2018 | 1659 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 275 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2004 | 49 | 0.110 |
Why?
| | Signal Transduction | 4 | 2012 | 4541 | 0.110 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 1447 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 957 | 0.110 |
Why?
| | Weight Loss | 2 | 1998 | 633 | 0.100 |
Why?
| | Androgens | 1 | 2004 | 165 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 185 | 0.100 |
Why?
| | Sirtuin 1 | 1 | 2012 | 29 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 563 | 0.100 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 93 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2024 | 12608 | 0.100 |
Why?
| | Postmenopause | 1 | 2004 | 300 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
| | Phosphorylation | 2 | 2013 | 1571 | 0.100 |
Why?
| | Estrogens | 1 | 2004 | 315 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 137 | 0.090 |
Why?
| | Arteries | 1 | 2013 | 250 | 0.090 |
Why?
| | Adiposity | 1 | 2015 | 468 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 175 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2161 | 0.090 |
Why?
| | Swine | 1 | 2013 | 704 | 0.090 |
Why?
| | Vasodilation | 1 | 2013 | 412 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 2987 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2006 | 1093 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2013 | 369 | 0.080 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 296 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2353 | 0.070 |
Why?
| | Cognition | 1 | 2004 | 980 | 0.070 |
Why?
| | Phosphates | 1 | 2007 | 160 | 0.070 |
Why?
| | Cholesterol, LDL | 2 | 2017 | 309 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3580 | 0.060 |
Why?
| | Endocrinologists | 1 | 2023 | 12 | 0.050 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 88 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 344 | 0.050 |
Why?
| | Adult | 7 | 2016 | 30719 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 223 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 137 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2004 | 1227 | 0.050 |
Why?
| | Insulin Glargine | 1 | 2012 | 73 | 0.050 |
Why?
| | Albuminuria | 1 | 2012 | 164 | 0.050 |
Why?
| | Animals | 5 | 2013 | 32102 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 2829 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1103 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 332 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2007 | 3914 | 0.050 |
Why?
| | Prospective Studies | 2 | 2021 | 6264 | 0.050 |
Why?
| | Adolescent | 2 | 2015 | 17890 | 0.050 |
Why?
| | Intensive Care Units | 1 | 2023 | 622 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 290 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 469 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 432 | 0.040 |
Why?
| | C-Peptide | 2 | 1998 | 138 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2012 | 351 | 0.040 |
Why?
| | Young Adult | 3 | 2015 | 10470 | 0.040 |
Why?
| | Dietary Fats, Unsaturated | 1 | 1998 | 21 | 0.040 |
Why?
| | Cholesterol | 2 | 1998 | 369 | 0.040 |
Why?
| | Triglycerides | 2 | 1998 | 473 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1650 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 757 | 0.040 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 43 | 0.040 |
Why?
| | Lipoproteins | 1 | 1998 | 162 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 15 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2800 | 0.030 |
Why?
| | Glucagon | 1 | 1996 | 93 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 78 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6165 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 147 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 1996 | 185 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2335 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 263 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 192 | 0.030 |
Why?
| | Lipids | 1 | 1998 | 588 | 0.030 |
Why?
| | Rats | 2 | 2007 | 5034 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2004 | 103 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 82 | 0.030 |
Why?
| | Androstadienes | 1 | 2003 | 97 | 0.030 |
Why?
| | Helminthiasis | 1 | 1993 | 11 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 667 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 1996 | 1127 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4440 | 0.030 |
Why?
| | Reference Values | 1 | 2004 | 744 | 0.030 |
Why?
| | Interleukin-4 | 1 | 1993 | 209 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 277 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 181 | 0.030 |
Why?
| | Self Report | 1 | 2015 | 698 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 123 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1044 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1993 | 328 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2004 | 278 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1265 | 0.020 |
Why?
| | PPAR gamma | 1 | 2012 | 185 | 0.020 |
Why?
| | Cattle | 1 | 2003 | 935 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1153 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1993 | 726 | 0.020 |
Why?
| | Cell Movement | 1 | 2003 | 867 | 0.020 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 24 | 0.020 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1436 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2012 | 3254 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4113 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4435 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6417 | 0.020 |
Why?
| | Risk | 1 | 2007 | 819 | 0.010 |
Why?
| | Kinetics | 1 | 2007 | 1569 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1998 | 36 | 0.010 |
Why?
| | Energy Intake | 1 | 1998 | 414 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 959 | 0.010 |
Why?
| | Antigens, Helminth | 1 | 1993 | 13 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 914 | 0.010 |
Why?
| | Chronic Disease | 1 | 1993 | 1598 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 965 | 0.000 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|